快报
欢迎光临蚂蚁淘在线！ 请登录 免费注册
商品
品牌
文章
热门搜索：
快报
品牌首页 品牌新闻 品牌简介 产品中心 品牌咨询 联系我们
品牌分类
品牌咨询
联系方式
公司地址
苏州工业园区生物纳米园A4#216
联系电话
4000-520-616 / 18915418616
传真号码
0512-67156496
电子邮箱
info@ebiomall.com
公司网址
https://www.ebiomall.com
蚂蚁淘在线 / 品牌中心 / Selleck Chemicals / Selleck Chemicals/Temsirolimus (CCI-779)/S1044

Selleck Chemicals/Temsirolimus (CCI-779)/S1044

价格
￥17400.00
货号：S1044
浏览量：127
品牌：Selleck Chemicals
服务
全国联保
正品保证
正规发票
签订合同
商品描述
DescriptionTemsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.
Targets
mTOR [1](Cell-free assay)
1.76 μM
In vitro

In the absence of FKBP12, Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM. Temsirolimus treatment at nanomolar concentrations (10 nM to <5 μm)="" displays="" a="" modest="" and="" selective="" antiproliferative="" activity="" via="" fkbp12-dependent="" mechanism,="" but="" can="" completely="" inhibit="" the="" proliferation="" of="" a="" broad="" panel="" of="" tumor="" cells="" at="" low="" micromolar="" concentrations="" (5-15="" μm),="" involving="" fkbp12-independent="" suppression="" of="" mtor="" signaling.="" temsirolimus="" treatment="" at="" micromolar="" but="" not="" nanomolar="" concentrations="" (20="" μm)="" causes="" a="" marked="" decline="" in="" global="" protein="" synthesis="" and="" disassembly="" of="" polyribosomes,="" accompanied="" by="" rapid="" increase="" in="" the="" phosphorylation="" of="" translation="" elongation="" factor="" eef2="" and="" the="" translation="" initiation="" factor="" eif2a.="">[1] Temsirolimus inhibits the phosphorylation of ribosomal protein S6, more potently in PTEN-positive DU145 cells than in PTEN-negative PC-3 cells, and inhibits cell growth and clonogenic survival of both cells in a concentration-dependent manner. [2] Temsirolimus (100 ng/mL) potently inhibits proliferation and induces apoptosis in primary human lymphoblastic leukemia (ALL) cells. [3]

Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
human HSC-4 cellNIC4botIem:5dHigbY5pcWKrdHnvckBie3OjeR?=NYDkdW9TUW6qaXLpeIlwdiCxZjDoeY1idiCKU1OtOEBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTF|IH7NM1jzSXNCVkeHUh?=
human L-363 cellMljYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MUnJcohq[mm2aX;uJI9nKGi3bXHuJGwuOzZ|IHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOFIhdk1?NGLJcZRUSU6JRWK=
human Ramos-2G6-4C10 cellNGjR[I1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=MmjLTY5pcWKrdHnvckBwiCqdX3hckBT[W2xcz2yS|YuPENzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|QzKG6PM2rXWHNCVkeHUh?=
human SBC-1 cellNUPKRW1jT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NV7CZnNWUW6qaXLpeIlwdiCxZjDoeY1idiCVQlOtNUBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDR2IH7NNYj4PFlCW0GQR1XS
human MHH-PREB-1 cellMkLES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?M3TKNWlvcGmkaYTpc44hd2ZiaIXtZY4hVUiKLWDSSWIuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwNEm1JI5OM{Hj[XNCVkeHUh?=
human LNCAP cellsM4PpXnBzd2yrZnXyZZRqd25iYYPzZZk>MVyzJIRigXN?NIDSc5dCdnSrcILvcIlnXKjdHn2[UBi[3Srdnn0fUBi2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;MD61JI5OMlfrNlE1Ozh3N{m=
human HH cellMnHJS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NF3qRYNKdmirYnn0bY9vKG:oIHj1cYFvKEiKIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD62OlQhdk1?MVfTRW5ITVJ?
human TYK-nu cellMkPLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MlTPTY5pcWKrdHnvckBwiCqdX3hckBVYUtvboWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc4QCCwTR?=NGT6[ZhUSU6JRWK=
human H4 cellNUizZ3ByT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=M1PrPWlvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC3JI5OMVPTRW5ITVJ?
human K5 cellNFvZXHVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGs2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|MzDuUS=>MkX0V2FPT0WU
human PA-1 cellMYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?MWjJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkS3JI5OM{XsUHNCVkeHUh?=
human SK-NEP-1 cellMULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?NGjBXndKdmirYnn0bY9vKG:oIHj1cYFvKFONLV7FVE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS52OTDuUS=>MnnMV2FPT0WU
human 697 cellNXX6VnZTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NUfNVINLUW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlchdk1?NHfvcIZUSU6JRWK=
human CTB-1 cellMUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?MmO1TY5pcWKrdHnvckBwiCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuPVMhdk1?NYjKb4JXW0GQR1XS
human DB cellMlfwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NWP0V|dGUW6qaXLpeIlwdiCxZjDoeY1idiCGQjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNVIhdk1?NEKxPVNUSU6JRWK=
human MLMA cellNUO0N5NrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NVfJR5A{UW6qaXLpeIlwdiCxZjDoeY1idiCPTF3BJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4{OSCwTR?=MoTpV2FPT0WU
human GAMG cellNGDpe4tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MmfqTY5pcWKrdHnvckBwiCqdX3hckBISU2JIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz64NkBvVQ>?NVrrbY9NW0GQR1XS
human JVM-3 cellMV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?M3LMdWlvcGmkaYTpc44hd2ZiaIXtZY4hUl[PLUOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlk2KG6PMmjHV2FPT0WU
human LAMA-84 cellNFzaWoxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=M2TNR2lvcGmkaYTpc44hd2ZiaIXtZY4hVEGPQT24OEBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvODNibl2=NVLGbIVSW0GQR1XS
human RPMI-8226 cellNHS3OopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=Mn2zTY5pcWKrdHnvckBwiCqdX3hckBTWE2LLUiyNlYh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF01NjF3IH7NNVKV2trW0GQR1XS
human MOLT-4 cellNHvvWVVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=M2nIPGlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4{OSCwTR?=NIfsZ3hUSU6JRWK=
human CAMA-1 cellNGL5dnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MXHJcohq[mm2aX;uJI9nKGi3bXHuJGNCVUFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuO|chdk1?MmDwV2FPT0WU
human NCI-SNU-1 cellNUe0cHNHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NF1R3ZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwOEGgcm0>NFG0WpNUSU6JRWK=
human SW780 cellNVr5TZp3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=NVnpO4FqUW6qaXLpeIlwdiCxZjDoeY1idiCVV{e4NEBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVQvQDNibl2=MVrTRW5ITVJ?
human H9 cellNED3eo5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=NF7wbpVKdmirYnn0bY9vKG:oIHj1cYFvKEh7IHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND64PEBvVQ>?NIrKW|FUSU6JRWK=
human BE-13 cellM3;Tc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7NH;De5hKdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE46OSCwTR?=MXLTRW5ITVJ?
human ES8 cellM2CzN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7MVfJcohq[mm2aX;uJI9nKGi3bXHuJGVUQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwMkegcm0>NFLi[XVUSU6JRWK=
human DEL cellMkD3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MXvJcohq[mm2aX;uJI9nKGi3bXHuJGRGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNE[gcm0>NFz6epNUSU6JRWK=
human QIMR-WIL cellNIj0NodIem:5dHigbY5pcWKrdHnvckBie3OjeR?=NYMUphxUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{Ggcm0>NUHmdIJzW0GQR1XS
human CGTH-W-1 cellMn7pS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MUTJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU44PSCwTR?=M{HYO3NCVkeHUh?=
human CHL-1 cellMlPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NVPG[WxzUW6qaXLpeIlwdiCxZjDoeY1idiCFSFytNUBkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQDZibl2=M4TFW3NCVkeHUh?=
human A2780 cellNVvU[|B6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MWJcohq[mm2aX;uJI9nKGi3bXHuJGEzPzhyIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT64PEBvVQ>?NUfI[FV{W0GQR1XS
human VA-ES-BJ cellMoHKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NULtRXhNUW6qaXLpeIlwdiCxZjDoeY1idiCYQT3FV{1DUiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwOTDuUS=>NEPTWWNUSU6JRWK=
human BB65-RCC cellMYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?MmW4TY5pcWKrdHnvckBwiCqdX3hckBDSjZ3LWLDR{BkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVchdk1?NYkSmlGW0GQR1XS
human D-566MG cellM1rhTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7M1jRSGlvcGmkaYTpc44hd2ZiaIXtZY4hTC13NkNS{BkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOTZibl2=MVvTRW5ITVJ?
human MDA468 cellsNUjDOFlCWHKxbHnm[ZJifGmxbjDhd5NigQ>?NXLCe2JGOyCmYYnzM3vrUWFvfGmycn;sbYZmemG2aYlJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBOFY5KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDNWHMh[XO|YYmsJGlEPTB;ODDuUS=>M4r6R|IyPDN6NUe5
human HO-1-N-1 cellM1jhOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7M3PNOmlvcGmkaYTpc44hd2ZiaIXtZY4hUE9vMT3OMVEh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5Nige,:jDDJR|UxRThwMjDuUS=>NYPFXFJUW0GQR1XS
human RS4-11 cellNUXDOlhZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MYTJcohq[mm2aX;uJI9nKGi3bXHuJHJUPC1zMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuOFUhdk1?M1Hwe3NCVkeHUh?=
human PC-3 cellNV7Fc3k2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MYnJcohq[mm2aX;uJI9nKGi3bXHuJHBENTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD17LkG0JI5OMVXTRW5ITVJ?
human NB69 cellMkfmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?M17wNGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUmuOFYhdk1?NXBWJZDW0GQR1XS
human HGC-27 cellMWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?NEXhcY5KdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{BkWyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVkvPiCwTR?=Mkm2V2FPT0WU
human NCI-H720 cellNUfR[Yk1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=M3Hs[2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi3NlAh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF06NjZ{IH7NMVLTRW5ITVJ?
human NCI-H292 cellMlPhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NUf2dlh4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTlwOESgcm0>NFHHSZZUSU6JRWK=
human A3-KAW cellMnLZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?MYLJcohq[mm2aX;uJI9nKGi3bXHuJGE{NUuDVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGwMlQ{KG6PNH7tfWlUSU6JRWK=
human DU-4475 cellM1WwOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7MUPJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTR2N{WgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU44OyCwTR?=NEfXTGlUSU6JRWK=
human HuH-7 cellNIPqOHNIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MlLTTY5pcWKrdHnvckBwiCqdX3hckBJfUhvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGyMlMzKG6PMoL5V2FPT0WU
human J-RT3-T3-5 cellNFP0WI9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGouWlR|LWSzMVUh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF0yOi5|ODDuUS=>NF;RVIZUSU6JRWK=
human VM-CUB-1 cellNF;sOWRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=NHXXV45KdmirYnn0bY9vKG:oIHj1cYFvKF[PLVPVRk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTJwNkegcm0>M1y1VnNCVkeHUh?=
human MOLT-16 cellM{XkNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7NEHEToZKdmirYnn0bY9vKG:oIHj1cYFvKE2RTGStNVYh[2WubDDndo94fGhiaX6gZUBkWyuIIpZYJqdGm2eTDhd5NigSxiSVO1NF0yOi56NDDuUS=>MmPHV2FPT0WU
human KG-1 cellM36xOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7NVfFUnl[UW6qaXLpeIlwdiCxZjDoeY1idiCNRz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVIvQSCwTR?=MVXTRW5ITVJ?
human P12-ICHIKAWA cellNFS5bFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=M37lRWlvcGmkaYTpc44hd2ZiaIXtZY4hWDF{LVnDTGlMSVeDIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUOuNFEhdk1?M1vJc3NCVkeHUh?=
human ACN cellNGHXZ4pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=MmHnTY5pcWKrdHnvckBwiCqdX3hckBCS05iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMz6wNkBvVQ>?NWfFR4JPW0GQR1XS
human COLO-684 cellM{ Vmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7MVrJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vNki0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVMvOzFibl2=Mnf3V2FPT0WU
human T-24 cellMlzBS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NF;E[ZdKdmirYnn0bY9vKG:oIHj1cYFvKFRvMkSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xN{45PiCwTR?=M{6PXNCVkeHUh?=
human AGS cellMYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?M{nqcGlvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUSuNVEhdk1?NWLpU|hkW0GQR1XS
human EW-13 cellMljMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?NFnXbo5KdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVQvPTRibl2=M3TLSXNCVkeHUh?=
human SW962 cellNWTwUGU1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm=MX;Jcohq[mm2aX;uJI9nKGi3bXHuJHNYQTZ{IHPlcIwh3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUWuOVkhdk1?NXHRfGcxW0GQR1XS
human EW-11 cellMof6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?M2rGT2lvcGmkaYTpc44hd2ZiaIXtZY4hTVdvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xOU43KG6PM4jPcXNCVkeHUh?=
human RXF393 cellM3zCWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7M1m1dmlvcGmkaYTpc44hd2ZiaIXtZY4hWliIM{mzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvPjZibl2=MmPyV2FPT0WU
human EoL-1-cell cellM{XOTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7MlXPTY5pcWKrdHnvckBwiCqdX3hckBGd0xvMT3j[YxtKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTZwMTDuUS=>NYfPeZdEW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
MethodsTest IndexPMID
Western blot
p-mTOR / mTOR / p-S6 / S6 / p-4E-BP1 / 4E-BP1 ;

PubMed: 23291985

The mTOR inhibitor temsirolimus inhibits the activation of mTOR and its downstream molecules in esophageal cancer cells. Three esophageal cancer cell lines (TE-1, TE-8, and TE-10) were treated with different concentrations of temsirolimus (0–1000nM) and western blot was performed with appropriate antibodies to detect the expression of mTOR and its downstream effectors. β-actin was served as an internal control.

p-rS6 / rS6 / p-AKT /AKT ;

PubMed: 22039466

C,D, Phosphorylation of rS6 (P-rS6) and Akt (P-Akt T308 and P-Akt S473) after treatment with indicated doses of temsirolimus for 72 hrs in temsirolimus-sensitive (C) or temsirolimus-resistant (D) cells was determined by Western blotting. Expression of total rS6 and Akt protein serves as loading controls.

23291985 22039466
Immunofluorescence
NRF2;

PubMed: 22848625

Ectopic expression of Nrf2 (red) and nuclear staining with Dapi (blue) after a 6 hour drug incubation. Yellow numbers represent the percent of cells with nuclear Nrf2 +/− the standard deviation. Scale bar = 10 µM.

22848625
Growth inhibition assay
Cell growth (HGC-3 cells) ;

PubMed: 30866995

Effect of temsirolimus on the growth of HGC-3 and -20 cells in primary culture.

Cell viability ;

PubMed: 22039466

A,B, Endometrial cancer cells were treated with increasing doses of temsirolimus for 72 hrs. Results are separated by (A) sensitivity or (B) resistance as determined by cell viability.

30866995 22039466
In vivoIn the NOD/SCID xenograft models with human ALL, Temsirolimus treatment at 10 mg/kg/day produces a decrease in peripheral blood blasts and in splenomegaly [3] Administration of Temsirolimus (20 mg/kg i.p. 5 days/week) significantly delays the growth of DAOY xenografts by 160% after 1 week and 240% after 2 weeks, compared with controls. Single high-dose of Temsirolimus (100 mg/kg i.p) treatment induces 37% regression of tumor volume within 1 week. Temsirolimus treatment for 2 weeks also delays the growth of rapamycin-resistant U251 xenografts by 148%. [4] Inhibition of mTOR by Temsirolimus improves performance on four different behavioral tasks and decreases aggregate formation in a mouse model of Huntington disease. [5] Administration of Temsirolimus induces significant dose-dependent, antitumor responses against subcutaneous growth of 8226, OPM-2, and U266 xenografts with ED50 of 20 mg/kg and 2 mg/kg for 8226 and OPM-2, respectively, which are associated with inhibited proliferation and angiogenesis, induction of apoptosis, and reduction in tumor cell size. [6]
Selleck Chemicals一直专注于生命科学领域高端试剂的开发与研究，旨在以最优价格为客户提供最优质的科研试剂服务。我们的产品包括抗体，重组蛋白，干扰rna，多肽，小分子激酶抑制剂等。Selleck Chemicals拥有一支热情与活力并存，经验与技术兼备的技术支持与客户服务团队，凭借在生命科学领域的多年研发经验，公司与多达2万多个客户建立了长期稳定的合作关系，其中包括世界各大制药厂，生物科技公司，医院及各大临床诊断实验室，世界各著名高校、研究所以及政府机关。